Chiral Hydroxypiperidine Resolution with Dynamic Racemization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing chiral hydroxypiperidine intermediates for Btk inhibitors like ibrutinib face limitations in yield and stereochemistry, particularly in enzymatic kinetic resolutions, which often result in maximum theoretical yields of only 50% due to the conversion of one enantiomer, and lack dynamic kinetic resolutions.
Innovation Solution
A process involving enzymatic kinetic resolution using Subtilisin or Savinase enzyme and an acyl donor, optionally with a racemization catalyst, to convert racemic chiral hydroxypiperidine to an enantioenriched form with greater than 20% enantiomeric excess, utilizing dynamic kinetic resolution to enhance conversion and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If enzymatic kinetic resolution is used to prepare chiral hydroxypiperidine, then enantiomeric excess is improved, but yield is limited to maximum theoretical 50%
Solution Approach 1:
The patent applies dynamic kinetic resolution by combining enzymatic kinetic resolution with in-situ racemization. The system dynamically converts the unreacted enantiomer back to the reactive form, allowing continuous conversion beyond the static 50% limitation. This is achieved by using a enzyme (e.g., lipase, esterase) for kinetic resolution coupled with a base catalyst for racemization, enabling yields exceeding 50% while maintaining high enantiomeric excess.
Solution Approach 2:
The patent implements continuous useful action by maintaining both the kinetic resolution reaction and the racemization reaction simultaneously in the same system. The unreacted enantiomer is continuously racemized and fed back into the kinetic resolution process, ensuring that the useful action of enantiomer conversion continues until complete consumption of the starting material, thereby overcoming the yield limitation.
2Ease of manufacture
If conventional enzymatic resolution is used, then process simplicity is maintained, but enantiomeric excess and yield are limited
Solution Approach 1:
The patent merges two processes - enzymatic kinetic resolution and chemical racemization - into a single integrated dynamic kinetic resolution process. This combination allows the system to achieve high enantiomeric excess (>90%) and high yield (>50%) simultaneously, overcoming the limitations of conventional enzymatic resolution while maintaining relative process simplicity through one-pot operation.
Solution Approach 2:
The patent changes the reaction parameters by adjusting pH, temperature, and catalyst ratios to optimize both the enzymatic kinetic resolution and the chemical racemization. By controlling these parameters, the system achieves high enantiomeric excess and high yield simultaneously, improving upon conventional methods without significantly complicating the manufacturing process.
3Manufacturing precision
If biocatalytic reduction with KRED is used, then stereochemistry is improved, but cost and complexity increase
Solution Approach 1:
The patent uses inexpensive, easily obtainable enzymes (such as commercial lipases or esterases) and simple base catalysts instead of expensive KRED enzymes. These enzymes can be used in disposable form or easily regenerated, reducing both cost and process complexity while achieving comparable or superior stereochemical outcomes through dynamic kinetic resolution.
Solution Approach 2:
The patent changes the catalytic system from expensive KRED enzymes to more economical enzymes combined with simple base catalysts. By optimizing reaction parameters such as pH, temperature, and catalyst loading, the system achieves high stereochemical purity with a simpler, more cost-effective process that does not require complex enzyme engineering or expensive cofactors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves enantioenriched chiral hydroxypiperidine with enantiomeric excess greater than 20%, potentially up to 98%, and supports the synthesis of Btk inhibitors like ibrutinib with improved yield and selectivity.
Implementation Method 1
A process involving enzymatic kinetic resolution using Subtilisin or Savinase enzyme and an acyl donor
Implementation Method 2
dynamic kinetic resolutions may overcome the yield limitation by racemising the remaining unreacted enantiomer
Data Source
AI summary
Disclosed is a process for the preparation of certain intermediates, e.g. the following compound: (I) which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.